Hepatotoxins

Affron Associated with Improvements in Psychological Symptoms of Menopause According to New Study

Retrieved on: 
Tuesday, June 15, 2021
Hormones, Endocrine system, Organ systems, Hepatotoxins, Prolactin releasers, Spices, Pregnanes, Progestogens, Menopause, Estrogen, Saffron, Medroxyprogesterone acetate

The saffron extract, administered for 12 weeks at 28 mg at day, was associated with greater improvements in psychological symptoms.

Key Points: 
  • The saffron extract, administered for 12 weeks at 28 mg at day, was associated with greater improvements in psychological symptoms.
  • Affron is produced and marketed by Pharmactive using green proprietary technology to extract pure, highly concentrated saffron.
  • "This is the first study of affron examining menopause symptoms in average perimenopausal women," explains Alberto Espinel, Manager of Strategic R&D in Active and Functional Natural Ingredients for Pharmactive.
  • "This means that in comparison to other botanical extracts that target menopause symptoms, affron doesn't have undesirable estrogenic effects.

CreakyJoints Reports that Women Endure Symptoms of Inflammatory Arthritis Despite Availability of Medications Proven Safe for Pregnant and Lactating Mothers

Retrieved on: 
Friday, June 11, 2021
General Health, Women, Consumer, Health, Pharmaceutical, Medical specialties, Clinical medicine, Medicine, Rheumatology, Autoimmune diseases, Arthritis, Hepatotoxins, Biotechnology, Rheumatoid arthritis, Nonsteroidal anti-inflammatory drug, Biopharmaceutical, TNF inhibitor

Data published in 2011 and 2012 demonstrated that TNFi medications (biologics) were safe to use during pregnancy and lactation in women with inflammatory forms of arthritis.

Key Points: 
  • Data published in 2011 and 2012 demonstrated that TNFi medications (biologics) were safe to use during pregnancy and lactation in women with inflammatory forms of arthritis.
  • Among those who were prescribed TNFis, 18 percent of women continued these medications through pregnancy post-2012 versus only 5 percent of women who continued these medications pre-2012 (p=0.006).
  • Forty percent of women felt that no medications were safe to use in pregnancy, whereas 41 percent selected prednisone (41%), TNFi (15%), NSAIDs (11%), hydroxychloroquine (9%), and acetaminophen (2%) as safe medications.
  • Most women were white (77%), college-educated (68%), and had rheumatoid arthritis (RA) (89%), but other inflammatory arthritis diagnoses were also represented.

PLx Pharma Inc. to Present at Upcoming Healthcare Industry Conferences

Retrieved on: 
Wednesday, June 9, 2021
Health sciences, Pharmacology, Drugs, Hepatotoxins, Dosage forms, Aspirin, Commercialization of traditional medicines, Pharma, Modified-release dosage

It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.

Key Points: 
  • It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.
  • PLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform to provide more effective and safer products.
  • The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract.
  • To learn more aboutPLx Pharma Inc. and its pipeline, pleasevisit www.plxpharma.com .

Labelling update regarding the use of non-steroidal anti-inflammatory drugs (NSAIDs) beyond 20 weeks of pregnancy and risk of kidney damage to unborn babies

Retrieved on: 
Tuesday, June 8, 2021
Hepatotoxins, Nonsteroidal anti-inflammatory drugs, Medical specialties, Obstetrics, Human reproduction, Health, Pregnancy, Drugs in pregnancy, Diclofenac

Issue: The use of non-steroid anti-inflammatory drugs (NSAIDs), starting from approximately 20 weeks of pregnancy or later, may cause rare but serious kidney problems in an unborn baby.

Key Points: 
  • Issue: The use of non-steroid anti-inflammatory drugs (NSAIDs), starting from approximately 20 weeks of pregnancy or later, may cause rare but serious kidney problems in an unborn baby.
  • What to do: Donot use NSAIDs from approximately 20 to 28 weeks of pregnancy, unless advised to do so by your healthcare professional.
  • The use of NSAIDs remains contraindicated (must not be used) in the last trimester of pregnancy (i.e., beyond 28 weeks to the end of pregnancy).
  • Do not use NSAIDs starting from around 20 to 28 weeks of pregnancy, unless advised to do so by your healthcare professional.

Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral

Retrieved on: 
Tuesday, June 8, 2021
Hepatotoxins, Chemical substances, Medical specialties, Chemical compounds, Management of HIV/AIDS, Zidovudine, Reverse-transcriptase inhibitor, HIV, Integrase inhibitor, Rilpivirine, Discovery and development of nucleoside and nucleotide reverse-transcriptase inhibitors

The research findings, published in Nature Communications, detailed additional mechanistic, drug product stability, pharmacokinetic, and toxicology studies supporting XVIR-110s profile as a potential best-in-class once-yearly antiretroviral agent.

Key Points: 
  • The research findings, published in Nature Communications, detailed additional mechanistic, drug product stability, pharmacokinetic, and toxicology studies supporting XVIR-110s profile as a potential best-in-class once-yearly antiretroviral agent.
  • Integrase inhibitors, in addition to capsid inhibitors and nucleoside reverse transcriptase inhibitors, are a class of agents under investigation as long-acting antiretroviral therapies.
  • Preclinical pharmacokinetic and toxicology studies conducted to date support the development of XVIR-110 as a potential once-yearly antiretroviral therapeutic for HIV treatment and prevention.
  • Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiretroviral therapeutics.

Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences

Retrieved on: 
Monday, June 7, 2021
Biotechnology, Pharmaceutical, Health, Other Health, Drugs, Nonsteroidal anti-inflammatory drugs, Hepatotoxins, Salicylic acids, Aspirin, Commercialization of traditional medicines, In Germany, Organ systems, Opioid, Medical specialties, Antibe Therapeutics

A link to the webcast of each event will be available on the News and Events section of the Companys website at antibethera.com .

Key Points: 
  • A link to the webcast of each event will be available on the News and Events section of the Companys website at antibethera.com .
  • Following the presentations, a replay of the webcasts will be available on the website for 90 days.
  • Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions.
  • Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-protective alternative to low-dose aspirin.

AHF: Lessons from 40 Years of AIDS, ‘The Other Pandemic,’ Must Guide Global Response to COVID-19

Retrieved on: 
Friday, June 4, 2021
White House, Federal Government, AIDS, Public policy, Government, Health, Healthcare reform, Public policy, Infectious diseases, Medical specialties, Health, Azides, Hepatotoxins, Zidovudine, HIV/AIDS, Chemical substances, AIDS Healthcare Foundation

Forty years of painful lessons from AIDS offer applicable lessons for our global fight against COVID-19, lessons that should not be ignored, said Michael Weinstein, president of AHF.

Key Points: 
  • Forty years of painful lessons from AIDS offer applicable lessons for our global fight against COVID-19, lessons that should not be ignored, said Michael Weinstein, president of AHF.
  • For years we have needed to radically overhaul and change the architecture of our global public health system and its structures.
  • Thankfully, the 1996 introduction of lifesaving combined drug antiretroviral therapies (ART)the so-called AIDS drug cocktail saved countless millions from death.
  • However, HIV/AIDS remains a deadly global health issue, taking the lives of nearly 700,000 people annually around the world.

Global HIV Pre-Exposure Prophylaxis (HIV PrEP) Disease Analysis Report 2021: Uptake of PrEP is Expected to Continue Following Positive European Reimbursement Decisions - ResearchAndMarkets.com

Retrieved on: 
Friday, June 4, 2021
Health, Pharmaceutical, Hepatotoxins, Medicine, Clinical medicine, Prevention of HIV/AIDS, HIV/AIDS, Pre-exposure prophylaxis, Emtricitabine/tenofovir, Management of HIV/AIDS, Prep, Neutralizing antibody, Zidovudine

The "Disease Analysis: HIV Pre-Exposure Prophylaxis (HIV PrEP)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: HIV Pre-Exposure Prophylaxis (HIV PrEP)" report has been added to ResearchAndMarkets.com's offering.
  • However, PrEP remains underutilized due to poor awareness and lack of/limited reimbursement in some European countries, though uptake is increasing due to recent favorable reimbursement decisions in Germany, Spain, England, Wales, and Northern Ireland, as well as Gilead's marketing efforts.
  • Within the EU and UK, Truvada is the only approved agent for PrEP but generates minimal sales due to generic competition since July 2017.
  • There are currently six agents in clinical development for pharmacological PrEP, comprising five antiretrovirals and a single broadly neutralizing antibody.

World HIV Treatment Forecast and Market Analysis Report 2021-2027: Market will be Driven by Patients Switching Over from Gilead's Dlder STRs - Genvoya, Stribild, Atripla, Complera, Odefsey - ResearchAndMarkets.com

Retrieved on: 
Friday, June 4, 2021
Infectious diseases, Pharmaceutical, Health, Chemical compounds, Organic compounds, Chemistry, Chloroarenes, Non-nucleoside reverse transcriptase inhibitors, Hepatotoxins, Antiretroviral drugs, Nitriles, Management of HIV/AIDS, Lenacapavir, ViiV Healthcare, HIV

The "HIV Treatment Forecast and Market Analysis to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HIV Treatment Forecast and Market Analysis to 2027" report has been added to ResearchAndMarkets.com's offering.
  • ViiV Healthcare has maintained its second-place position in the HIV treatment market and is likely to grow its revenues due to new INSTI-based drug launches.
  • HIV/AIDS drugs, on average, take 8.9 years from Phase I to approval, which is in line with the overall infectious disease space.
  • There are three new drugs in late-phase development for the treatment of heavily treatment-experienced patients, namely lenacapavir (capsid inhibitor), islatravir/doravirine (reverse transcriptase translocation inhibitor), and Vyrologix (CCR5 inhibitor).

Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets

Retrieved on: 
Thursday, June 3, 2021
Health sciences, Health care, Health, Dosage forms, Pharmacy, Hepatotoxins, Chemical engineering, Pharmaceutical industry, Tablet, Combined oral contraceptive pill, Adherence, Polypill

The availability of these additional strength tablets follows a U.S. Food & Drug Administration (FDA) approval on April 15, 2021.

Key Points: 
  • The availability of these additional strength tablets follows a U.S. Food & Drug Administration (FDA) approval on April 15, 2021.
  • In addition to the original 20 mg strength tablets, XPOVIO is now available in 40 mg, 50 mg, and 60 mg strength tablets.
  • XPOVIO tablets are available in seven different package sizes to help healthcare providers individualize the dosing and administration of XPOVIO based on patient needs.
  • The additional dosage strength tablets may also increase patient compliance by simplifying their treatment regimen and reducing the pill burden experienced by some patients.